GHRP-6

Background

Growth hormone-releasing peptide‑6 (GHRP‑6) is a synthetic hexapeptide growth hormone secretagogue (GHS), originally developed in the 1980s–1990s as part of the first generation of growth hormone‑releasing peptides (GHRPs) designed to stimulate pituitary growth hormone (GH) secretion through a receptor distinct from the growth hormone–releasing hormone (GHRH) receptor.[13] GHRP‑6 is also referred to in the literature as His‑D‑Trp‑Ala‑Trp‑D‑Phe‑Lys‑NH₂, a ghrelin mimetic, and a ligand of the growth hormone secretagogue receptor type 1a (GHSR‑1a).[13][15]

Early work established GHRP‑6 as a potent stimulator of GH release in multiple species, including humans, with activity independent of hypothalamic GHRH and partially additive or synergistic when co‑administered with GHRH.[13] It became a key pharmacological tool for characterizing the GHSR‑1a/ghrelin axis and for exploring therapeutic strategies in GH deficiency, cachexia, and organ protection.[13][15]

Despite extensive preclinical pharmacology and limited exploratory clinical use, GHRP‑6 itself has not progressed to full regulatory approval as a therapeutic in the United States or European Union; instead, several non‑peptide and peptide GHSR agonists (e.g., macimorelin, anamorelin) have advanced further in clinical development.[13]

Mechanism of action

Receptor targets

GHRP‑6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHSR‑1a), a G‑protein‑coupled receptor identified as the canonical receptor for both GHRPs and endogenous ghrelin.[13][15] GHSR‑1a is highly expressed in the anterior pituitary and hypothalamus, as well as in peripheral tissues including heart, vasculature, kidney, and immune cells.[13]

GHRP‑6 exhibits:

• High‑affinity binding to GHSR‑1a, activating intracellular signaling pathways such as Gq/11‑phospholipase C–IP₃/Ca²⁺, PKC, and downstream MAPK/ERK cascades.[13][15]
• Functional agonism comparable to ghrelin in terms of stimulating GH release and activating orexigenic neuropeptide Y/agouti‑related peptide (NPY/AgRP) neurons in the arcuate nucleus of the hypothalamus.[15]

Some studies also suggest off‑target or context‑dependent interactions with other receptors or signaling pathways, including cardioprotective and cytoprotective signaling not fully explained by pituitary GH release alone, but these mechanisms remain incompletely defined.[12][13]

Endocrine and metabolic actions

Systemic administration of GHRP‑6 produces:

• Rapid, dose‑dependent GH release from the anterior pituitary, with consequent increases in circulating insulin‑like growth factor‑1 (IGF‑1) in responsive species and humans.[13][15]
• Activation of hypothalamic ghrelin signaling networks, including orexigenic NPY/AgRP neurons, indicating ghrelin‑like central actions.[15]
• Modulation of metabolic pathways in peripheral tissues; for example, in renal tubular epithelial cells, GHRP‑6 hydrogel altered amino acid and fatty acid metabolism via mTOR–p70S6K signaling during acute kidney injury (AKI).[3]

Cytoprotective and anti‑inflammatory effects

Preclinical work indicates that GHRP‑6 can:

• Activate prosurvival signaling in cardiomyocytes, reducing doxorubicin‑induced mitochondrial damage, oxidative stress, and fibrosis.[12][14]
• Attenuate neutrophilic inflammation, improve alveolar‑capillary permeability, and limit evolution to pulmonary fibrosis in acute lung injury models.[4]
• Promote myoblast differentiation and collagen I expression via IGF‑1–related pathways in vitro.[11]

These effects may involve both GHSR‑1a–dependent and additional pathways (e.g., modulation of cytokines, extracellular matrix remodeling, and mitochondrial function).[11][12][13]

Evidence summary

Endocrine and CNS engagement

A recent mouse study using intranasal ghrelin mimetics evaluated whether GHRP‑6 can engage central ghrelin signaling.[15] In this experiment, intranasal administration of ghrelin, GHRP‑6, or MK‑0677 was compared; effective compounds induced c‑Fos activation in GHSR‑expressing hypothalamic neurons and modulated feeding‑related circuits.[15] Although the primary emphasis was mechanistic, the study provided direct evidence that GHRP‑6 can access and activate brain ghrelin pathways when delivered intranasally, supporting its classification as a ghrelin mimetic.[15] Sample sizes were typical for neuropharmacology studies (e.g., n≈6–10 per group), though detailed numbers vary by experiment.[15]

Systemic GHRP‑6 had been previously shown to stimulate GH release in humans and rats, with transient elevations in serum GH consistent with GHSR activation.[15][13] Detailed early human pharmacodynamic trials are summarized in review form but remain relatively small (tens of subjects) and exploratory.[13]

Cardioprotection and organ protection

A 2024 preclinical study investigated GHRP‑6 for prevention of doxorubicin‑induced cardiomyopathy and multi‑organ toxicity in rats.[12][14] Adult rats received doxorubicin with or without concomitant GHRP‑6; outcomes included left ventricular ejection fraction, histopathology, mitochondrial integrity, and markers of oxidative stress.[12][14]

• GHRP‑6 markedly attenuated left ventricular dysfunction, reduced cardiomyocyte apoptosis, and limited structural remodeling compared with doxorubicin alone.[12][14]
• Protective effects were also observed in extra‑cardiac organs, consistent with systemic mitigation of doxorubicin toxicity.[12][14]

Although robust within the animal model (group sizes on the order of 8–12 animals per arm), these findings remain preclinical; there are no corresponding randomized clinical trials in humans.

Acute lung injury and pulmonary fibrosis

In a murine model of acute lung injury induced by lipopolysaccharide (LPS) or zymosan plus platelet activating factor, GHRP‑6 was tested in both acute and chronic settings.[4]

• Single or repeated GHRP‑6 dosing reduced neutrophilic alveolitis, improved lung compliance, and decreased serum interleukin‑1β levels in the acute phase.[4]
• In longer‑term assessments up to 28 days, GHRP‑6 preserved lung architecture and reduced progression to interstitial fibrosis.[4]

These findings indicate significant anti‑inflammatory and anti‑fibrotic effects in rodents but lack clinical corroboration.

Renal protection and metabolic modulation

A 2025 study developed a self‑assembling GHRP‑6 hydrogel for AKI therapy in mice.[3]

• In ischemia–reperfusion–induced AKI, GHRP‑6 hydrogel enhanced survival of renal tubular epithelial cells, improved functional recovery, and altered renal metabolomic profiles, with enrichment of spermidine, L‑glutamine, and acetyl‑CoA.[3]
• Mechanistically, benefits were linked to activation of the mTOR–p70S6K pathway, suggesting metabolic reprogramming of tubular cells as a protective mechanism.[3]

Again, these data are preclinical, and the hydrogel formulation specifically has not been evaluated in humans.

Skeletal muscle and myogenesis

In vitro, a GHRP‑6‑biotin conjugate promoted myoblast differentiation.[11]

• In C2C12 myoblasts, the conjugate increased expression of myogenic markers (myosin heavy chain, myogenin) and collagen type I, mediated at least partly by upregulation of IGF‑1.[11]
• The study suggests potential utility for muscle repair or conditioning, but evidence is limited to cell culture.[11]

Clinical data

Review of available literature indicates fragmented and limited clinical data for GHRP‑6, largely involving:

• Acute GH stimulation testing and endocrine profiling in small human cohorts.[13][15]
• Occasional uncontrolled or compassionate‑use interventions in myocardial ischemia or critical illness, without rigorous randomized designs.[13]

No large, randomized phase 2 or 3 clinical trials of GHRP‑6 for any indication in humans were identified in current registries or peer‑reviewed reports.[13]

Clinical and research uses

Established or approved uses

• No approved therapeutic indications for GHRP‑6 exist in the United States or European Union as of the latest accessible regulatory and clinical trial data.[13]

Investigational and research applications

GHRP‑6 is primarily used as a research tool:

• To probe GHSR‑1a/ghrelin signaling in endocrine and neurobiology experiments.[13][15]
• As a model GHS in preclinical studies of cardioprotection, renoprotection, and lung injury.[3][4][12]
• In in vitro systems to study myogenesis and extracellular matrix regulation.[11]

Potential therapeutic niches proposed based on preclinical data include:

• Prevention or attenuation of chemotherapy‑induced cardiomyopathy, particularly doxorubicin‑related.[12][14]
• Treatment or prevention of acute lung injury/acute respiratory distress syndrome and subsequent pulmonary fibrosis.[4]
• Renal protection and promotion of recovery after AKI, including biomaterial‑based delivery (GHRP‑6 hydrogel).[3]
• Adjunctive use in ischemic stroke when co‑administered with other growth factors such as recombinant human EGF, though data are preclinical.[10]

These remain hypothesis‑generating indications without confirmatory human trials.

Dosing context

Reported doses are experimental and should not be extrapolated to clinical prescribing.

• In rodent cardioprotection studies against doxorubicin, GHRP‑6 was administered systemically at doses in the low‑to‑moderate microgram/kg range, given repeatedly during chemotherapy cycles.[12][14]
• In acute lung injury models, mice received single or multiple GHRP‑6 doses after LPS or zymosan/PAF exposure; doses were chosen to span a preclinical dose–response curve (e.g., low, medium, high μg/kg ranges).[4]
• In the AKI hydrogel study, GHRP‑6 was incorporated into a self‑assembling hydrogel applied locally; the peptide load per hydrogel volume was optimized for renal protection in mice and is not directly comparable to systemic dosing.[3]
• In early human studies (as summarized in reviews), GHRP‑6 has been administered intravenously or subcutaneously in acute settings for GH stimulation tests, often as single bolus doses, but detailed dosing regimens vary and are not standardized.[13]

Because of substantial interspecies differences and the absence of approved indications, no consensus therapeutic dosing regimen in humans can be derived from the literature.

Safety profile

Preclinical safety and tolerability

Across multiple animal models, GHRP‑6 has generally shown a favorable acute and subacute safety profile:[13]

• In cardioprotection experiments, GHRP‑6 co‑administration did not exacerbate doxorubicin‑induced toxicity and instead reduced histologic damage in heart and other organs.[12][14]
• In lung injury and AKI models, GHRP‑6 reduced inflammatory markers and tissue injury without apparent worsening of systemic parameters.[3][4]

However, these studies are not designed as formal toxicology programs, and long‑term carcinogenicity, reproductive toxicity, and high‑dose safety have not been comprehensively characterized.

Endocrine and metabolic risks

By stimulating GH and IGF‑1, GHRP‑6 could theoretically:

• Influence glucose metabolism, potentially impairing glucose tolerance or promoting insulin resistance with chronic exposure, as observed with other GH‑elevating agents.[13]
• Promote cell proliferation or growth of GH‑responsive tissues, raising concerns in patients with active malignancy, proliferative retinopathy, or uncontrolled acromegaly.[13]

Potential adverse effects and contraindications (theoretical)

Based on its pharmacology and experience with other GH secretagogues and ghrelin mimetics, plausible adverse effects and precautions include:[13][15]

• Transient flushing, headache, or injection‑site reactions with parenteral administration (reported with related GHSs).
• Edema, arthralgia, or carpal tunnel–like symptoms due to GH/IGF‑1 axis activation.
• Caution in patients with active cancer, proliferative diabetic retinopathy, or established acromegaly, where GH/IGF‑1 stimulation is undesirable.
• Caution in severe cardiovascular disease due to potential fluid retention or hemodynamic effects, despite preclinical cardioprotective signals.

Robust human safety data for chronic use are lacking; consequently, risk–benefit profiles remain uncertain.

Regulatory status

• United States: GHRP‑6 is not approved by the U.S. Food and Drug Administration (FDA) for any indication. It does not appear in FDA drug labeling databases as a licensed medicinal product.[13]
• European Union: There is no centralized EMA marketing authorization for GHRP‑6, and it is not listed among approved peptide therapeutics in current EMA documentation.[13]
• GHRP‑6 is typically categorized as a research chemical or experimental peptide. Some related GHSR agonists (e.g., macimorelin for GH deficiency diagnosis, anamorelin for cancer cachexia in some jurisdictions) have obtained approvals, underscoring that the drug class is clinically validated, but GHRP‑6 itself has not progressed beyond early‑phase or exploratory evaluation.[13]

As of available data, GHRP‑6 remains an investigational and preclinical tool compound without formal therapeutic authorization in major regulatory regions.